Observational studyAnnals of internal medicine2019
Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study.
Observational study in Annals of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Efficacy and safety of short-course antibiotic therapy for community-acquired pneumonia in adults: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Antibiotic treatment for 7 days versus 14 days in patients with uncomplicated bloodstream infections: a Systematic review and meta-analysis of randomized controlled trials and trial sequential analysis.Frontiers in medicine · 2025Pooled it
- Prevalence of fever of unidentified aetiology in East African adolescents and adults: a systematic review and meta-analysis.Infectious diseases of poverty · 2023Pooled it
- A systematic review and Bayesian meta-analysis of the antibiotic treatment courses in AECOPD.Frontiers in pharmacology · 2023Pooled it
- Determinants of non-adherence to antibiotic treatment guidelines in hospitalized adults with suspected community-acquired pneumonia: a prospective study.Antimicrobial resistance and infection control · 2024Trial
- Multiplex real-time PCR in non-invasive respiratory samples to reduce antibiotic use in community-acquired pneumonia: a randomised trial.Nature communications · 2024Trial
- Trial
- Trial
- Biomarker guided antibiotic stewardship in community acquired pneumonia: A randomized controlled trial.PloS one · 2024Trial
- Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study.BMC geriatrics · 2022Trial
- Reducing overuse of antibiotics at discharge home: A single-center mixed methods pilot study.American journal of infection control · 2022Trial
- Electronic Clinical Quality Measures of Antibiotic Use in Hospitalized Adults With Uncomplicated Community-Acquired Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Significant Publications on Infectious Diseases Pharmacotherapy in 2024.Journal of pharmacy practice · 2026Review
- Streamlining antibiotic use in community acquired pneumonia: A quality improvement initiative.Journal of hospital medicine · 2026Observational
- Host-microbiome archetypes differentiate infection from pathogen carriage in the human lower airway.Nature communications · 2026Article
- Impact of incorporating electronic medical record tools on optimal antibiotic durations at discharge for uncomplicated community-acquired pneumonia: a quasi-experimental study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Are there racial/ethnic differences in antibiotic treatment of community acquired pneumonia in the inpatient setting?PloS one · 2026Article
- Accessibility of big data in medicine: adjusting the duration of antibiotic treatment for gram-negative bloodstream infections.Health systems (Basingstoke, England) · 2026Article
- Respiratory multiplex PCR and antimicrobial treatment modification in hospitalized patients with community-acquired pneumonia.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Predicting length of hospital stay in community-acquired pneumonia using clinical and treatment factors: a retrospective study with restricted cubic spline and piecewise regression analysis.Frontiers in public health · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
Background: Randomized trials demonstrate no benefit from antibiotic treatment exceeding the shortest effective duration. Objective: To examine predictors and outcomes associated with excess duration of antibiotic treatment. Design: Retrospective cohort study. Setting: 43 hospitals in the Michigan Hospital Medicine Safety Consortium. Patients: 6481 general care medical patients with pneumonia. Measurements: The primary outcome was the rate of excess antibiotic treatment duration (excess days per 30-day period). Excess days were calculated by subtracting each patient's shortest effective (expected) treatment duration (based on time to clinical stability, pathogen, and pneumonia classification [community-acquired vs. health care-associated]) from the actual duration. Negative binomial generalized estimating equations (GEEs) were used to calculate rate ratios to assess predictors of 30-day rates of excess duration. Patient outcomes, assessed at 30 days via the medical record and telephone calls, were evaluated using logit GEEs that adjusted for patient characteristics and probability of treatment. Results: Two thirds (67.8% [4391 of 6481]) of patients received excess antibiotic therapy. Antibiotics prescribed at discharge accounted for 93.2% of excess duration. Patients who had respiratory cultures or nonculture diagnostic testing, had a longer stay, received a high-risk antibiotic in the prior 90 days, had community-acquired pneumonia, or did not have a total antibiotic treatment duration documented at discharge were more likely to receive excess treatment. Excess treatment was not associated with lower rates of any adverse outcomes, including death, readmission, emergency department visit, or Clostridioides difficile infection. Each excess day of treatment was associated with a 5% increase in the odds of antibiotic-associated adverse events reported by patients after discharge. Limitation: Retrospective design; not all patients could be contacted to report 30-day outcomes. Conclusion: Patients hospitalized with pneumonia often receive excess antibiotic therapy. Excess antibiotic treatment was associated with patient-reported adverse events. Future interventions should focus on whether reducing excess treatment and improving documentation at discharge improves outcomes. Primary Funding Source: Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network as part of the BCBSM Value Partnerships program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.